Hrt Financial LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

  • $15.6 Billion
  • Q1 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$0.21 - $0.43 $6,114 - $12,520
29,118 New
29,118 $6,000
Q3 2022

Nov 14, 2022
BUY
$6.04 - $9.66 $136,757 - $218,721
22,642 New
22,642 $170,000
Q4 2021

Feb 14, 2022
SELL
$5.12 - $8.19 $99,133 - $158,574
-19,362 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$6.68 - $9.1 $129,338 - $176,194
19,362 New
19,362 $129,000
Q2 2021

Aug 16, 2021
SELL
$7.82 - $9.23 $145,983 - $172,305
-18,668 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$8.44 - $12.66 $157,557 - $236,336
18,668 New
18,668 $165,000

Others Institutions Holding EIGR

# of Institutions
6
Shares Held
748K
Call Options Held
0
Put Options Held
0
View Full List

About Eiger BioPharmaceuticals, Inc.

EIGR Quotes by TradingView
  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $556M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email